JPWO2018098412A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018098412A5 JPWO2018098412A5 JP2019528512A JP2019528512A JPWO2018098412A5 JP WO2018098412 A5 JPWO2018098412 A5 JP WO2018098412A5 JP 2019528512 A JP2019528512 A JP 2019528512A JP 2019528512 A JP2019528512 A JP 2019528512A JP WO2018098412 A5 JPWO2018098412 A5 JP WO2018098412A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- pharmaceutically acceptable
- halo
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 125000001475 halogen functional group Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- -1 3-pyridinyl Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000005879 dioxolanyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 3
- 201000011240 frontotemporal dementia Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 201000011585 Pick's disease Diseases 0.000 claims 2
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010070976 Craniocerebral injury Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 claims 1
- 206010034606 Peripheral neuropathy Diseases 0.000 claims 1
- 206010037175 Psychiatric disease Diseases 0.000 claims 1
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 201000004810 vascular dementia Diseases 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426631P | 2016-11-28 | 2016-11-28 | |
| US62/426,631 | 2016-11-28 | ||
| PCT/US2017/063231 WO2018098412A1 (en) | 2016-11-28 | 2017-11-27 | Gsk-3 inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019535788A JP2019535788A (ja) | 2019-12-12 |
| JP2019535788A5 JP2019535788A5 (es) | 2020-11-19 |
| JPWO2018098412A5 true JPWO2018098412A5 (es) | 2022-03-01 |
| JP7114591B2 JP7114591B2 (ja) | 2022-08-08 |
Family
ID=60655130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528512A Active JP7114591B2 (ja) | 2016-11-28 | 2017-11-27 | Ｇｓｋ－３阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10752609B2 (es) |
| EP (1) | EP3544613B1 (es) |
| JP (1) | JP7114591B2 (es) |
| KR (1) | KR102575990B1 (es) |
| CN (1) | CN110545817B (es) |
| ES (1) | ES2878078T3 (es) |
| MA (1) | MA46889A (es) |
| WO (1) | WO2018098412A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102455408B1 (ko) * | 2016-11-28 | 2022-10-14 | 브리스톨-마이어스 스큅 컴퍼니 | Gsk-3 억제제로서의 피리미딘 카르복스아미드 |
| MA54546A (fr) * | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
| CN116178281B (zh) * | 2023-04-27 | 2023-07-21 | 中国药科大学 | 一种双功能免疫抑制剂及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| JP5241834B2 (ja) * | 2007-07-19 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての複素環アミド化合物 |
| WO2012024179A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| KR102292433B1 (ko) * | 2013-11-06 | 2021-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Gsk-3 억제제로서 유용한 치환된 피리딘 유도체 |
| MX2016005760A (es) * | 2013-11-06 | 2016-07-18 | Squibb Bristol Myers Co | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). |
| WO2016144792A1 (en) * | 2015-03-06 | 2016-09-15 | Alpharmagen, Llc | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| KR102455408B1 (ko) * | 2016-11-28 | 2022-10-14 | 브리스톨-마이어스 스큅 컴퍼니 | Gsk-3 억제제로서의 피리미딘 카르복스아미드 |
-
2017
- 2017-11-27 CN CN201780084344.7A patent/CN110545817B/zh active Active
- 2017-11-27 EP EP17812188.5A patent/EP3544613B1/en active Active
- 2017-11-27 ES ES17812188T patent/ES2878078T3/es active Active
- 2017-11-27 JP JP2019528512A patent/JP7114591B2/ja active Active
- 2017-11-27 KR KR1020197018285A patent/KR102575990B1/ko active IP Right Grant
- 2017-11-27 WO PCT/US2017/063231 patent/WO2018098412A1/en active Application Filing
- 2017-11-27 MA MA046889A patent/MA46889A/fr unknown
- 2017-11-27 US US16/463,467 patent/US10752609B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2345070C2 (ru) | Производные аминоиндазолов в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции | |
| JP2024023271A (ja) | 化合物 | |
| CN100567279C (zh) | 烷基哌嗪-和烷基高哌嗪-羧酸酯衍生物、其制备方法及其作为faah酶抑制剂的用途 | |
| JP5532366B2 (ja) | ピラジンカルボキサミド化合物 | |
| JP4110324B2 (ja) | 新規インダゾール誘導体 | |
| JP6364472B2 (ja) | 抗がんおよび抗増殖活性を示すｎ−アシル−ｎ’−（ピリジン−２−イル）尿素および類似体 | |
| TWI540133B (zh) | 嘧啶衍生物之製造方法 | |
| JP2020537657A5 (es) | ||
| JP6854386B2 (ja) | リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物 | |
| IL168723A (en) | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the preparation of medicaments for the treatment of cancer | |
| CA2438991A1 (en) | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| JP2010513458A (ja) | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 | |
| JP2007524682A (ja) | 代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド | |
| CA2477774A1 (en) | Indolylmaleimide derivatives | |
| JP2010519328A (ja) | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 | |
| JP2019535788A5 (es) | ||
| TW202208367A (zh) | 作為ｉｌ－１７調節劑之咪唑并嗒類 | |
| JP2003505383A5 (es) | ||
| WO2010018328A1 (fr) | Composes d'azétidines polysubstitues, leur préparation et leur application en thérapeutique | |
| JPWO2018098412A5 (es) | ||
| JP2022518359A (ja) | テトラゾロン置換ステロイド及びその使用 | |
| HUT76827A (en) | Benzamidin derivative with ltb4-receptor antagonist activity, its preparation and use as a drug | |
| JP7114591B2 (ja) | Ｇｓｋ－３阻害剤 | |
| JP2019535790A5 (es) | ||
| JP2006117677A5 (es) |